Additional file 1: Supplemental Figure S1. Landmark analysis, excluding patients who died within 3 months. Kaplan–Meier survival analysis for all-cause mortality. The prognosis of patients with immune-related adverse events (irAEs) was significantly better than that of patients without irAEs (P < 0.001). This was also detected in patients with a cardiovascular history (P = 0.014) and in those without a cardiovascular history (P = 0.001).